Biogen Shares Aduhelm Data In Alzheimer's Disease At 128 Weeks

  • Biogen Inc BIIB has announced new data from the long-term extension phase of the Phase 3 trials of Aduhelm (aducanumab-avwa) in Alzheimer's disease.
  • The data exhibited that after nearly two and a half years of treatment (128 weeks) with Aduhelm, patients continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid-beta plaques, and plasma p-tau181. 
  • The data also show that in both Phase 3 trials, at 78 weeks, patients with reduced levels of plasma p-tau181 had less clinical decline than those whose plasma p-tau181 levels were not reduced.
  • Related: Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
  • Data from the long-term extension study showed that ADUHELM significantly reduced amyloid-beta plaque levels out to Week 132. The data also showed that Aduhelm decreased plasma p-tau181 levels at 128 weeks. 
  • Patients with more effective amyloid-beta clearance (SUVR lower than 1.1 by 78 weeks) also had greater decreases in p-tau181 at week 128.
  • Data showed that patients with a reduction in plasma p-tau181, an exploratory endpoint, had less clinical progression across all four clinical endpoints measuring cognition and function in both Phase 3 trials at Week 78.
  • Price Action: BIIB shares are up 2.51% at $202.31 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralAlzheimer's diseaseBriefsPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!